---
title: "Obefazimod (ABX464) in Ulcerative colitis: Product comparison"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Product comparison. Topics: Network meta-analysis of phase 3 induction trials including obefazimod, Mechanism of action relative to authorized immunological treatments, Marketed and investigational classes named by the manufacturer as competitors, Company cross-trial comparison of maintenance clinical remission with approved UC products, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/product-comparison"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Network meta-analysis of phase 3 induction trials including obefazimod

> “Thirty-three induction trials involving 17 therapies were included.”
> “Upadacitinib demonstrated the highest relative efficacy for clinical remission (risk ratio, 6.90; 95% confidence interval, 3.54-12.45; P score, 0.95; high confidence) and endoscopic improvement (risk ratio, 5.29; 95% confidence interval, 3.38-8.28; P score, 0.97; moderate confidence).”
> “In AT-naïve patients, obefazimod and upadacitinib showed the highest efficacy, whereas in AT-experienced patients, upadacitinib, ustekinumab, and tofacitinib ranked highest.”
> “Novel therapies, like obefazimod and subcutaneous guselkumab, may represent highly effective alternatives.”

Source: [Olivera et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42838315/)

<a id="topic-2.1.2.14-2"></a>

### Mechanism of action relative to authorized immunological treatments

> “To our knowledge, currently there are no similar immunological treatments with a mechanism of action based on enhanced expression of a single microRNA miR-124 with marketing authorization granted by competent regulatory authorities.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.14-3"></a>

### Marketed and investigational classes named by the manufacturer as competitors

> “The molecules on the market and in development have various mechanisms of action and are primarily: (i) TNF-alpha inhibitors; (ii) IL-12/23 inhibitors; (iii) anti-integrin antibodies; (iv) IL-23 inhibitors; (v) JAK inhibitors; (vi) S1P receptor agonists; or (vii) TL1A inhibitors.”
> “Current oral therapies that target inflammatory pathways include JAK inhibitors (such as tofacitinib and upadacitinib), as well as agents that reduce the trafficking of inflammatory cells, such as S1P receptor agonists (e.g., ozanimod and etrasimod).”
> “Merck, Roche, and Teva/Sanofi are all potential future competitors based on recent acquisitions of TL1A molecules.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “In this context, market research following the announcement of the ABTECT Phase 3 induction results in July 2025 indicates that obefazimod may emerge as the future market leader in UC, potentially outperforming both currently approved therapies and anticipated future entrants, including TL1A inhibitors and oral IL-23 agents.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

<a id="topic-2.1.2.14-4"></a>

### Company cross-trial comparison of maintenance clinical remission with approved UC products

> “Maintenance Efficacy of FDA/EMA Approved UC Products: Clinical Remission* at 52 Weeks Induction Responders Only”
> “For illustrative purposes only. Not a head-to-head comparison. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across trials.”

Source: [Abivax corporate presentation (2026)](https://ir.abivax.com/static-files/ecf996c4-f156-4dac-8e1e-5c4e7cfb8e7d)

<a id="topic-2.1.2.14-5"></a>

### Emerging oral small molecules for ulcerative colitis

> “Some molecules, such as miRNA-124 upregulators, JAKi, S1P modulators, and LANCL2 agonists, may enrich our therapeutic armamentarium in UC management.”

Source: [Lanzotti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42251531/)

<a id="topic-2.1.2.14-6"></a>

### Analyst comment on a possible boxed warning relative to JAK inhibitors and TL1A inhibitors

> “We also remain mindful of the possibility of a Black Box warning, which would limit commercial differentiation against JAK inhibitors and negatively position obefazimod against emerging classes in IBD, including TL1A inhibitors.”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
